Mechanism of action The mechanism of action of<unk>  in the treatment of schizophrenia is unclear. However, it is thought to be an agonist at the trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptors. This mechanism of action is unique among available antipsychotics, which generally antagonize dopamine receptors (especially dopamine D2 receptor). Pharmacokinetics The precise pharmacokinetic profile of<unk>  has not been reported, though the developer has suggested that the pharmacokinetic data supports once daily dosing.
Ulotaront
Cloforex
Choroid
Midaflur
Foltx
Craniotabes
Ateronon
Euryphon